Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MDH1 | P40925 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7201519 | 0.89 | TAAR1 (0.55) | ALDH1A1PTGS2PPARDCYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL9267842 | 0.88 | TAAR1 (0.53) | ALDH1A1PTGS2PPARDCYP2C9CYP2C19 | |
| SCHEMBL12869161 | 0.86 | ALDH1A1 (0.63) | ALDH1A1MEN1KMT2APPARDCYP2C9 | |
| SCHEMBL2292200 | 0.85 | PPARA (0.55) | ALDH1A1MAPT | |
| SCHEMBL12251782 | 0.84 | ITGB3 (0.48) | — | |
| SCHEMBL1431250 | 0.84 | CYP4A11 (0.57) | ALDH1A1MEN1KMT2APTGS2PPARD | |
| SCHEMBL1429054 | 0.83 | PTGS2 (0.49) | ALDH1A1MEN1KMT2APTGS2PPARD | |
| SCHEMBL5491120 | 0.82 | PTGS2 (0.54) | ALDH1A1MEN1KMT2APTGS2PPARD | |
| SCHEMBL4262134 | 0.81 | ADRB2 (0.58) | ALDH1A1MEN1KMT2APTGS2PPARD | |
| SCHEMBL8481490 | 0.81 | PTGS2 (0.53) | ALDH1A1MEN1KMT2APTGS2PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008494-B2 | 2-(4-{4-[N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidino]-butyl}phenoxy)-N-(3-dimethylaminopropyl)acetamide dimethanesulfonate; promoting hydration of mucosal surfaces; Sjogren's disease, esophagitis, pneumonia, asthma, otitis, constipation, chronic diverticulitis, rhinosinusitis | PARION SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20080171879-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171879-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | SCN2A, CACNA1B, HCN4 | ALDH1A1 1627/4885MEN1 2369/4885KMT2A 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.